Molecular Partners Ag Stock Price To Sales
| MOLN Stock | USD 3.77 0.10 2.58% |
Molecular Partners AG fundamentals help investors to digest information that contributes to Molecular Partners' financial success or failures. It also enables traders to predict the movement of Molecular Stock. The fundamental analysis module provides a way to measure Molecular Partners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Molecular Partners stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 16.36 | 18.47 |
Molecular | Price To Sales |
Molecular Partners AG Company Price To Sales Analysis
Molecular Partners' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Molecular Partners Price To Sales | 18.45 X |
Most of Molecular Partners' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Partners AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Molecular Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Molecular Partners is extremely important. It helps to project a fair market value of Molecular Stock properly, considering its historical fundamentals such as Price To Sales. Since Molecular Partners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Molecular Partners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Molecular Partners' interrelated accounts and indicators.
Click cells to compare fundamentals
Molecular Price To Sales Historical Pattern
Today, most investors in Molecular Partners Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Molecular Partners' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Molecular Partners price to sales as a starting point in their analysis.
Molecular Partners Price To Sales |
| Timeline |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Molecular Price To Sales Ratio
Price To Sales Ratio |
|
Based on the latest financial disclosure, Molecular Partners AG has a Price To Sales of 18.4473 times. This is 13.8% lower than that of the Biotechnology sector and 81.25% lower than that of the Health Care industry. The price to sales for all United States stocks is 61.54% lower than that of the firm.
Molecular Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Partners' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics of similar companies.Molecular Partners is currently under evaluation in price to sales category among related companies.
Molecular Partners Current Valuation Drivers
We derive many important indicators used in calculating different scores of Molecular Partners from analyzing Molecular Partners' financial statements. These drivers represent accounts that assess Molecular Partners' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Molecular Partners' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 407.6M | 433.1M | 543.4M | 196.6M | 115.2M | 109.4M | |
| Enterprise Value | 334.4M | 306.6M | 477.6M | 113.5M | (68.1M) | (64.7M) |
Molecular Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (16.13) % | ||||
| Current Valuation | (56.09 M) | ||||
| Shares Outstanding | 32.87 M | ||||
| Shares Owned By Institutions | 2.63 % | ||||
| Number Of Shares Shorted | 56.35 K | ||||
| Price To Earning | 1.85 X | ||||
| Price To Book | 0.67 X | ||||
| Price To Sales | 18.45 X | ||||
| Revenue | 7.04 M | ||||
| Gross Profit | 138.85 M | ||||
| EBITDA | (58.69 M) | ||||
| Net Income | (61.98 M) | ||||
| Cash And Equivalents | 267.13 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 3.65 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.37 X | ||||
| Book Value Per Share | 5.37 X | ||||
| Cash Flow From Operations | (55.18 M) | ||||
| Short Ratio | 12.93 X | ||||
| Earnings Per Share | (2.07) X | ||||
| Target Price | 8.98 | ||||
| Number Of Employees | 167 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 128.52 M | ||||
| Total Asset | 198.35 M | ||||
| Retained Earnings | (191.75 M) | ||||
| Working Capital | 178.04 M | ||||
| Net Asset | 198.35 M |
About Molecular Partners Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Partners AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Partners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Partners AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Molecular Partners Piotroski F Score and Molecular Partners Altman Z Score analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Molecular Stock analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stocks Directory Find actively traded stocks across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |
Is Molecular Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Revenue Per Share 0.215 | Quarterly Revenue Growth (0.62) | Return On Assets (0.17) | Return On Equity (0.30) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.